Results 131 to 140 of about 1,825,523 (203)

Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. [PDF]

open access: yesRisk Anal
Kalkowska DA   +6 more
europepmc   +1 more source

[Vaccine-associated poliomyelitis: safety of the oral poliovirus vaccine, Brazil, 2013-2023Poliomielitis asociada a poliovirus derivados de la vacuna: seguridad de la vacuna oral contra la poliomielitis en Brasil, 2013-2023]. [PDF]

open access: yesRev Panam Salud Publica
Silva RMA   +14 more
europepmc   +1 more source

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.

open access: yesLancet Microbe
Godin A   +14 more
europepmc   +1 more source

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. [PDF]

open access: yesLancet Infect Dis
Rivera Mejía L   +11 more
europepmc   +1 more source

The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks.

open access: yesCell Host Microbe, 2021
Valesano AL   +9 more
europepmc   +1 more source

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization. [PDF]

open access: yesClin Infect Dis, 2018
Sarnquist C   +15 more
europepmc   +1 more source

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016.

open access: yesInt J Infect Dis, 2021
Ahmad M   +11 more
europepmc   +1 more source

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial. [PDF]

open access: yesLancet
Ochoge M   +20 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy